Citations

Clear

154 citation(s) found for "Levin, G".

Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward
Kelloff, Gary J. , Lippman, Scott M. , Dannenberg, Andrew J. , Sigman, Caroline C. , Pearce, Homer L., Reid, Brian J. , Szabó, Éva , Jordan, V. Craig , Spitz, Margaret R., Papadimitrakopoulou, Vali A., Lotan, Reuben, Aggarwal, Bharat B. , Bresalier, Robert S. , Kim, Jeri , Lu, Karen H. , Thomas, Melanie E., Rhodes, Helen, Brewer, Molly, Follen, Michele , Shin, Dong M. , Parnes, Howard L. , Siegfried, Jill M. , Evans, Alison A., Blot, William J. , Chow, Wong‐Ho , Blount, Patricia L., Wang, Kenneth K. , Lam, Stephen , Lee, J. Jack, Dubinett, Steven M., Engstrom, Paul F., Meyskens, Frank L. , O’Shaughnessy, Joyce , Hawk, Ernest T. , Levin, Bernard, Nelson, William G. , Hong, Waun Ki , Prevention, for the AACR Task Force on Cancer, Lee, J. Jack , Mills, Gordon B. , Arun, Banu , Maley, Carlo C. , Lee, J. Jack, Prevention, for the AACR Task Force on Cancer, Szabo, Eva , Lee, J Jack

Mayo Clinic

Clinical Cancer Research | June 8, 2006 | Volume: 12 | Issue: 12 | Pages: 3661-3697

10.1158/1078-0432.ccr-06-1104 | PMID 16778094 Get It

AbstractThis article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.
External Radiation of Brain Metastases From Renal Carcinoma: A Retrospective Study of 119 Patients From the M. D. Anderson Cancer Center
Davis, B. J. , Levin, Victor A. , Wroński, Marek , Maor, Moshe , Sawaya, Raymond

Mayo Clinic

Journal of Urology | January 17, 2006 | Volume: 159 | Issue: 2S | Pages: 618-618

10.1016/s0022-5347(01)63907-7 Get It

Genetically Characterized Positive Control Cell Lines Derived from Residual Clinical Blood Samples
Bernacki, Susan H. , Beck, Jeanne C., Stanković, Ana , Williams, Laurina O. , Amos, Jean, Snow-Bailey, Karen, Farkas, Daniel H., Friez, Michael J., Hantash, Feras, Matteson, Karla J., Monaghan, Kristin G. , Muralidharan, Kasinathan, Pratt, Victoria M. , Prior, Thomas W., Richie, Kristy L., Levin, Barbara C., Rohlfs, Elizabeth M., Schaefer, Frederick V., Shrimpton, Antony E., Spector, Elaine , Stolle, Catherine A., Strom, Charles M. , Thibodeau, Stephen N. , Cole, Eugene C., Goodman, Barbara K. , Stenzel, Timothy T.

Mayo Clinic

Clinical Chemistry | September 16, 2005 | Volume: 51 | Issue: 11 | Pages: 2013-2024

10.1373/clinchem.2005.048694 | PMID 16166172 Get It

AbstractBackground: Positive control materials for clinical diagnostic molecular genetic testing are in critically short supply. High-quality DNA that closely resembles DNA isolated from patient specimens can be obtained from Epstein–Barr virus (EBV)–transformed peripheral blood lymphocyte cell lines. Here we report the development of a process to (a) recover residual blood samples with clinically important mutations detected during routine medical care, (b) select samples likely to provide viable lymphocytes for EBV transformation, (c) establish stable cell lines and confirm the reported mutation(s), and (d) validate the cell lines for use as positive controls in clinical molecular genetic testing applications.Methods: A network of 32 genetic testing laboratories was established to obtain anonymous, residual clinical samples for transformation and to validate resulting cell lines for use as positive controls. Three panel meetings with experts in molecular genetic testing were held to evaluate results and formulate a process that could function in the context of current common practices in molecular diagnostic testing.Results: Thirteen laboratories submitted a total of 113 residual clinical blood samples with mutations for 14 genetic disorders. Forty-one EBV-transformed cell lines were established. Thirty-five individual point and deletion mutations were shown to be stable after 20 population doublings in culture. Thirty-three cell lines were characterized for specific mutations and validated for use as positive controls in clinical diagnostic applications.Conclusions: A process for producing and validating positive control cell lines from residual clinical blood samples has been developed. Sustainable implementation of the process could help alleviate the current shortage of positive control materials.
Epidemiology of large bowel cancer
Levin, Kenneth E., Dozois, Roger R.

Mayo Clinic

World Journal of Surgery | June 20, 2005 | Volume: 15 | Issue: 5 | Pages: 562-567

10.1007/bf01789199 | PMID 1949852 Get It

AbstractResults from epidemiologic studies have provided insights into the etiology of large bowel cancer. Markedly diverse incidences of colorectal cancer exist in various parts of the world and within different regions of a given country. Studies of migrant populations have revealed a role for environmental factors, particularly dietary, in the etiology of colorectal cancers. Genetic factors and inflammatory bowel disease also place certain individuals at increased risk. Sedentary lifestyle, cholecystectomy, and ureterosigmoidostomy may also increase the risk of developing large bowel cancer.